The 2mg GHK-Cu Dose Was Pulled From a Hat
Every GHK-Cu dosing chart repeats the same number, 2mg, and the number looks like a protocol precisely because it gets repeated so often, which is why it deserves scrutiny, because the figure came from community convention, with no trial behind it. This article traces where the 2mg convention came from and what the mouse data supports, then walks through the copper arithmetic behind the cycling debate and the solubility wall that picks your solvent, before closing on the honest limits that keep injected GHK-Cu in research-use territory. Everything here is community-sourced and nothing here is medical advice.
Every GHK-Cu dosing chart repeats the same number, 2mg, and the number looks like a protocol precisely because it gets repeated so often, which is why it deserves scrutiny, because the figure came from community convention, with no trial behind it. This article traces where the 2mg convention came from and what the mouse data supports, then walks through the copper arithmetic behind the cycling debate and the solubility wall that picks your solvent, before closing on the honest limits that keep injected GHK-Cu in research-use territory. Everything here is community-sourced and nothing here is medical advice.
I · The dose that appears in every dosing chart
The 2mg figure shows up identically across dosing charts and blend calculators, and the threads that repeat it carry no citation to the trial behind it.
In the sourcing corpus this site draws on, the number appears as settled fact, since the most consistent voice in that record, one prolific community educator, a knowledgeable amateur, states it flatly: “Normal dose of GHK-Cu is 2mg” [anecdotal] 1. The same figure anchors the Glow blends that dominate the copper-peptide market, because the 35/10/5 and 50/10/10 formulations are built around a 2mg draw of the GHK-Cu component, and the reconstitution math that converts a vial into a dose repeats across threads with identical numbers: 50mg plus 3ml of bac water gives 16.667mg per ml, so a 2mg dose is 0.12ml, which is 12 units on an insulin syringe 2. The community even jokes about the logic behind the blends, since newcomers are told to dose one constituent and “pretend the other two aren’t even there” [anecdotal] 2. The consistency is the interesting part, because a number repeated this often usually arrived from somewhere testable, and the trail back to a source keeps dissolving.
The contrast with a peptide that has a real pharmaceutical history makes the gap visible, since tesamorelin’s 2mg daily dose comes from the Egrifta trial program, which ran year-long studies at exactly that dose, and the molecule’s prescribing record gives the number an anchor 4. GHK-Cu carries no such anchor, because the compound was not developed as an injectable drug, so its 2mg arrived from somewhere else entirely, and the bluntest account in the corpus names that somewhere: “2mg is the ‘protocol dose’ that got pulled out of somebody’s hat with a rabbit years ago. It’s not really based on anything.” [anecdotal] 3. The disagreements run in both directions, because a competing claim that circulates on TikTok insists that 1mg saturates the response and 2mg is wasted, which the community’s reading of the mouse literature contradicts, so the same unanchored number gets attacked as too high and too low at once 5.
The Glow formulations carry the 2mg dose inside a fixed recipe, either 35mg of GHK-Cu with 10mg of BPC-157 and 5mg of TB-4 or the heavier 50/10/10 version. Reconstituted with 3ml of bac water, a 50mg vial runs 16.667mg per ml, so a 2mg draw is 0.12ml, which is 12 units on a standard insulin syringe. The community advice for blend dosing is to calculate the GHK-Cu component and ignore the other two peptides when drawing, because they arrive as passengers in the same volume.
II · The mouse record and the weekly dosing schedule
The animal literature runs on weekly dosing and systemic endpoints, which leaves the daily human injection dose without a source.
The mouse studies that exist are real, and they are the reason the compound has any reputation at all, since the record assembled in the corpus covers ulcerative-colitis and IBD models, SIRT1-related papers, a diabetic-ulcer dressing study, and preclinical findings pointing toward neuroprotection 6. One of the most striking lines in the corpus concerns the schedule, because the impressive mouse work did something the human protocols do not, and the educator flags it directly: “If you look on PubMed you’ll find that some of the most impressive mouse studies done on GHK-Cu actually used 1x/week dosing.” [anecdotal] 6. The community reads that as a lesson about mechanism, since GHK-Cu appears to trigger downstream pathways, including SIRT1-related signaling, that outlast the peptide itself, and the corpus’s metaphor for the behavior is worth quoting whole: “If I punch you in the face and run away the half life of you seeing me is about 10 seconds but the anger you feel afterwards would last for hours.” [anecdotal] 6.
The honest reading is that this evidence supports the molecule, and the protocol remains unsupported, because the mouse work dosed once a week and measured systemic and metabolic endpoints, which is a different question from whether a daily 2mg subcutaneous injection changes anything a human cares about 7. The neuroprotective line gets the community’s wry acknowledgment, since “The irony is that recent preclinical research with GHK-Cu points to it being neuroprotective and reducing amyloid plaques and cognitive impairment in aging mice” [anecdotal], and one contributor sums up the rodent record bluntly: “Glow/Klow peptides work miracles in rats, particularly GHK-Cu.” [anecdotal] 7. The promise lives in the mice, and the translation step from mouse to human dosing was skipped, so the weekly-schedule insight and the downstream-pathway mechanism stay as biology lessons, and no dosing manual grew from them, which is exactly the gap the 2mg convention fills by assertion 7.
The conventional reading of a short peptide half-life is that you have to dose constantly to keep levels up, and the mouse record suggests GHK-Cu works differently, since it triggers downstream signaling that continues after the molecule clears, which is why weekly dosing produced the effects that made the compound famous. The practical translation is that the community’s daily dosing habit may rest on a misunderstanding of the molecule’s biology, so the weekly mouse schedule deserves more attention than the dosing charts give it.
III · Zero human injection data
Injected GHK-Cu has no human injection trials, and the human studies on the record used topical or rectal routes.
The ceiling on all of this is the absence of human data, and the corpus is unusually disciplined about saying so, because the most quoted summary of the field comes from the same educator: “There are no reliable medical or research sources as injected GHK-Cu has never been tested in humans, only in mice. Human studies have all been topical. The best you’re gonna get is a protocol that an influencer pulled out of a magic hat along with a rabbit.” [anecdotal] 8. The route distinction matters, because topical human studies of GHK-Cu exist in the skin-care literature, and the 15-year-old human pilot the corpus can find delivered the peptide rectally for inflammatory bowel disease, so the human exposure that exists ran through cream and colon, with nothing delivered by syringe 7. “Subq GHK-Cu doesn’t have any human data either though.” [anecdotal] 8.
The community’s bluntest self-assessment is worth reading twice, because it names the epistemic situation exactly:
“GHK-Cu? It’s all made up. Any answer I give you would be me pulling horseshit out of my ass. We don’t actually know and everybody is doing whatever based on vibes. The mouse studies don’t even support how people are using it.”
Community educator, r/Peptides discourse, 2026
That passage describes the market precisely, because each dosing chart and stack recommendation for injected GHK-Cu descends from the same unanchored convention, and the people building those protocols are influencers without investigator standing 9. The evidence-honest position follows directly: the mouse data supports studying the molecule, and the copper arithmetic constrains the dose, but nothing in the record supports a specific human injection protocol, which is exactly why the 2mg number deserves the scrutiny this article gives it 9.
A cream puts peptide into skin tissue locally, and a rectal pilot reaches the gut lining, so neither route produces the systemic exposure that a subcutaneous injection would, while bioavailability and local concentration differ by route. The human data that exists therefore cannot be scaled into an injection dose, which leaves the subcutaneous protocol layer with no clinical floor.
IV · The copper math that ends the cycling debate
A 2mg dose carries about 0.3mg of elemental copper, a rounding error against normal daily intake, so cycling to prevent copper buildup protects against a problem that is not there.
The dosing question runs into a safety question quickly, because the peptide is about 15% copper by mass, and the community’s arithmetic on what a 2mg dose carries is specific enough to settle the matter. “A 2mg dose of GHK-Cu has about 0.3mg of elemental copper which is a small fraction of the max daily intake for copper (10mg) as well as the average daily intake (1-2mg).” [anecdotal] 10. The body also runs a dedicated clearance route for the metal, since excess copper leaves through biliary excretion, and that pathway can ramp to roughly 6mg per day when needed, so a few hundred micrograms of injected copper sits far below what the system already handles from food 10. For someone with normal copper metabolism the dose is chemistry trivia, and the interesting cases are people whose copper handling is impaired, the Wilson’s-type pattern, because for them the metal accumulates while clearance lags, which is precisely the population the labs exist for 11.
The cycling advice dies on the same math, because the community’s anti-cycling case has two legs, and the copper leg is the arithmetic above, since there is nothing to accumulate at 0.3mg per dose, while the pharmacology leg is even cleaner, because GHK-Cu has no receptor to desensitize in the first place: “GHK-Cu is particularly funny for this because it doesn’t even have a receptor that could be desensitized.” [anecdotal] 11. The corpus’s conclusion is flat: “I’ve never been able to find any evidence supporting the need to cycle GHK-Cu.” [anecdotal] 11. So the 5-on/2-off and four-to-twelve-week schedules that populate the peptide internet are solutions looking for a problem, and the community’s replacement is a lab draw, with the calendar shelved, since a baseline serum copper test before starting and periodic checks while using the compound catch the only real risk, impaired metabolism, far earlier than any rest schedule could 11.
The community’s copper guidance is concrete, because a baseline serum copper draw before the first injection and periodic repeats while using the compound, ordered through the self-pay lab services the gray market relies on, exist to catch the impaired-metabolism pattern early. For people with normal copper handling the result usually reads as a formality, which is fine, because the draw is cheap and the failure mode it guards against is the one that matters. The cycle schedule is ritual; the lab is the protection.
V · The solubility wall that picks your solvent
GHK-Cu acetate dissolves in PBS at roughly 5mg per ml at pH 7.2, about a third of what the standard recipe demands, and the phosphate attacks the copper.
The 2mg convention meets physics at the reconstitution step, because the standard recipe of 50mg in 3ml demands a concentration of 16.667mg per ml, and the compound cannot reach that strength in the solvent some users reach for first. The Cayman Chemical insert puts the number on the record, and the corpus quotes it directly: “The solubility of GHK-Cu (acetate) in PBS, ph 7.2, is approximately 5mg/ml.” 12. Phosphate buffered saline, the lab default for many peptides, dissolves GHK-Cu acetate at roughly a third of the required strength, so the standard 3ml recipe in PBS is physically impossible, and the chemistry gets worse from there, because “the phosphate in PBS very much does oxidize and corrode copper” [anecdotal] 12.
The practical conclusion is that bacteriostatic water is the right vehicle, and the community’s reasoning survives the chemistry, since benzyl alcohol, the 0.9% preservative in bac water, has no documented interaction with GHK-Cu, and the corrosion story belongs to phosphate, leaving the preservative out of it 12. The solubility ceiling also explains part of the dilution advice, because a 50mg vial reconstituted with 20ml of bac water drops to 2.5mg per ml, a strength the acetate handles easily, and the same 2mg dose then rides in a much larger volume 13. The dose survives the dilution, because the syringe math follows the concentration, so the 2mg that takes 12 units at standard strength takes several times that volume at the dilute recipe, and the sting reduction arrives as a side effect of the same change 13.
The reconstitution decision is a math problem you can solve on paper before the peptide arrives, because standard strength means 50mg with 3ml of bac water at 16.667mg per ml and a 2mg draw of 0.12ml, which is 12 units, whereas the dilute route means 50mg with 20ml at 2.5mg per ml and a 2mg draw of 0.8ml. Either route delivers the same 2mg, and the difference sits in the local concentration at the injection site and in whether the solvent can hold the peptide at all.
VI · The sting that made the dose famous
The most reported GHK-Cu side effect is the injection sting, and the community’s two fixes change the concentration while keeping the dose fixed.
The 2mg draw is also the dose people complain about, because GHK-Cu produces the most discussed injection-site reaction in the copper-peptide corner of the corpus, a delayed burning that starts one to two hours after the pin and can run twelve to eighteen hours 1. The community’s leading explanation is free copper, since many vials carry more copper than the GHK tripeptide can hold, and the excess ions irritate the tissue directly, a mechanism the educator tested by dipping copper test strips in his own drug solution and reading positive 14. Batch variance explains the mixed reports, because “Most of the GHK-Cu on the market has too much copper added to it.” [anecdotal], and a vial that does not sting is probably carrying less free copper, which reads as a quality signal 14.
The two fixes both change the concentration, which is the clue that the problem is local, since heavy dilution is the first lever, and the community phrase for it is characteristically direct: “If you dilute the effing hell out of it you can make it stingless.” [anecdotal], with the practical recipe being a 2mg dose drawn into 80 units of bac water 13. The second lever is a second peptide, because adding 10 to 15mg of GHK-Basic to a 50mg vial of GHK-Cu chelates the loose copper before it reaches the syringe: “You simply add 10-15mg of GHK-Basic to a 50mg vial of GHK-Cu and it’s pain-free.” [anecdotal] 14. The failures are informative too, since zinc supplements did nothing for the burning, and the lidocaine verdict is blunt: “As far as lidocaine goes I think it’s inappropriate.” [anecdotal] because it masks the pain without changing the tissue chemistry 14. GHK is a tripeptide, which the community reads as a safety advantage, since peptides under eight amino acids are generally non-immunogenic, and the house phrase for the whole approach is “The solution to pollution is dilution.” [anecdotal] 14.
GHK is three amino acids, and the community’s rule of thumb is that peptides under eight amino acids are generally non-immunogenic, which lowers the stakes of a purity question that would matter more for a large protein. The visible signals stay useful too, because a properly chelated GHK-Cu solution runs blue, and that color is one of the few checks a user can perform without a lab.
VII · The honest value of the 2mg convention
The honest summary is that 2mg is a community agreement with a plausible rationale and no human data behind it.
After the arithmetic and the chemistry, the convention deserves a fair valuation, because what the evidence supports is narrower than the dosing charts imply: the molecule shows real biological activity in mice, the copper load at 2mg is trivial for normal metabolizers, the solubility constraint rules out PBS, the sting has a credible mechanism with two working fixes, and there is no receptor to desensitize, so cycling protects nothing 14. The evidence stops short of the number itself, since no trial has ever run the schedule, the record is silent on the route’s effects on skin or recovery, and no human injection study has been documented 8. The tesa comparison sharpens the point, because tesamorelin’s 2mg daily dose sits on a published trial program, whereas GHK-Cu’s identical-looking 2mg sits on a hat 4.
The research-use frame is the only honest frame, and it is also the useful one, because a compound with this profile belongs in controlled research settings where the unknowns are named and the labs are run, with no place in consumer marketing where the dosing chart is the argument 9. The community that produced this corpus models the posture, since it runs serum copper labs, tests its vials, runs A/B tests on its own legs, and says out loud that the protocols are “all made up” [anecdotal] and refuses to pretend otherwise 8. The practical guidance that follows is short and specific: treat the 2mg convention as a starting hypothesis, saving the fact label for trial data, run the copper lab before and during use, keep PBS out of the vial, dilute hard or add GHK-Basic if the site burns, and expect most dosing questions to go unanswered until a real trial runs 8.
Injected GHK-Cu is a research compound, and this article is community-sourced education rather than medical advice, which means the 2mg convention should inform your reading of the field, with self-treatment left to a clinician. If you are evaluating the compound, the standing checklist is short: baseline serum copper before starting, periodic repeats while using, bac water for reconstitution, heavy dilution or GHK-Basic for the sting, and honest expectations about what the evidence does and does not cover.
Everything in this article is community-sourced, and every personal report carries the [anecdotal] label, the honest currency of a market with no clinical data on injected GHK-Cu. The 2mg convention is worth understanding precisely because it is a convention, since that understanding protects you from the two failure modes of this market, treating a hat-pulled number as settled science on one side and dismissing the molecule entirely because the protocol layer is weak on the other. Use the information for research purposes, take any question about your own health to a clinician, and this is not medical advice.
- Community discourse corpus (reddit-tracyisdad), cluster_sourcing_a §2 and §1: GHK-Cu and copper-peptide discourse is a core theme (60 comments), the sting/ISR theme appears 29 times across 614 analyzed comments, and the threads recognize the educator; §7.5: “Normal dose of GHK-Cu is 2mg.”
- cluster_sourcing_a §3.2: blend math for 50mg plus 3ml of bac water at 16.667mg per ml, 2mg equals 0.12ml or 12 units; newcomers told to “pretend the other two aren’t even there.”
- cluster_research_biohacking §3.3: “2mg is the ‘protocol dose’ that got pulled out of somebody’s hat with a rabbit years ago. It’s not really based on anything.”
- cluster_sourcing_a §3.1: tesamorelin 2mg per day dosing from the Egrifta trial program, with year-long studies and an 18-month trial (pubmed 31611038) anchoring the dose.
- cluster_sourcing_a §9: the “1mg saturates, 2mg is waste” claim circulating on TikTok is contradicted by trial data showing effects past that point.
- cluster_sourcing_a §7.5 and §3.2: PubMed mouse studies dosed once weekly; SIRT1 downstream signaling outlasts the peptide; the punch-in-the-face metaphor; §6 lists mouse UC/IBD and SIRT1 papers and a diabetic-ulcer dressing study.
- cluster_sourcing_a §7.5: “The irony is that recent preclinical research with GHK-Cu points to it being neuroprotective and reducing amyloid plaques and cognitive impairment in aging mice”; “Glow/Klow peptides work miracles in rats, particularly GHK-Cu.”; §6: the 15-year-old human IBD pilot delivered rectally.
- cluster_sourcing_b §7: “There are no reliable medical or research sources as injected GHK-Cu has never been tested in humans, only in mice. Human studies have all been topical. The best you’re gonna get is a protocol that an influencer pulled out of a magic hat along with a rabbit.”; §3.3: “Subq GHK-Cu doesn’t have any human data either though.”
- cluster_sourcing_b §3.3: “GHK-Cu? It’s all made up. Any answer I give you would be me pulling horseshit out of my ass. We don’t actually know and everybody is doing whatever based on vibes. The mouse studies don’t even support how people are using it.”; injected-GHK-Cu protocols are influencer-made.
- cluster_sourcing_a §7.5: “A 2mg dose of GHK-Cu has about 0.3mg of elemental copper which is a small fraction of the max daily intake for copper (10mg) as well as the average daily intake (1-2mg).”; §3.2: roughly 15% copper by mass, biliary excretion ramps to about 6mg per day, 10mg upper limit, 1 to 2mg average intake.
- cluster_sourcing_a §7.5: “I’ve never been able to find any evidence supporting the need to cycle GHK-Cu.”; cluster_research_biohacking §7: “doesn’t even have a receptor that could be desensitized”; §3.2: baseline plus periodic serum copper labs and the Wilson’s-type risk.
- cluster_sourcing_a §7.5 (Cayman Chemical insert): “The solubility of GHK-Cu (acetate) in PBS, ph 7.2, is approximately 5mg/ml”; §3.2: “the phosphate in PBS very much does oxidize and corrode copper”; no evidence benzyl alcohol oxidizes GHK-Cu.
- cluster_research_biohacking §3.3: “If you dilute the effing hell out of it you can make it stingless”; “Try 2mg of GHK-Cu in 80 units of bac”; cluster_sourcing_a §7.5: 20ml reconstitution drops the strength to 2.5mg per ml.
- cluster_sourcing_a §5 and §7.5: delayed burning one to two hours post-injection lasting twelve to eighteen hours; free-copper test-strip evidence; “Most of the GHK-Cu on the market has too much copper added to it”; GHK-Basic at 10 to 15mg per 50mg vial; zinc failure and the lidocaine judgment; cluster_research_biohacking §3.3: tripeptide, generally non-immunogenic under eight amino acids, “The solution to pollution is dilution.”